Lates News

According to Each AI Flash News, Open Source Securities released a research report on April 2nd, giving a "buy" rating to Wanmei Biology (603983.SH). The reasons for the rating mainly include: 1) a year-on-year revenue increase of 16.5% in 2025, a year-on-year net profit decrease of 27.6%, with slight pressure on profitability; 2) Continued efforts in core products, impressive performance in eye and skincare categories, increased brand promotion leading to higher sales expenses; 3) Continuous consolidation of advantages in segmented categories, upgrading product matrix and overall channel synergy. (Daily Economic News)